Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Total Liabilities (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Total Liabilities for 4 consecutive years, with $85.9 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 19.85% to $85.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.9 million through Dec 2025, down 19.85% year-over-year, with the annual reading at $85.9 million for FY2025, 19.85% down from the prior year.
  • Total Liabilities hit $85.9 million in Q4 2025 for NewAmsterdam Pharma, up from $58.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $107.1 million in Q4 2024 to a low of -$398.4 million in Q1 2023.
  • Historically, Total Liabilities has averaged -$36.3 million across 4 years, with a median of $58.4 million in 2025.
  • Biggest five-year swings in Total Liabilities: surged 119.24% in 2024 and later tumbled 46.45% in 2025.
  • Year by year, Total Liabilities stood at $48.0 million in 2022, then rose by 22.26% to $58.7 million in 2023, then surged by 82.47% to $107.1 million in 2024, then dropped by 19.85% to $85.9 million in 2025.
  • Business Quant data shows Total Liabilities for NAMS at $85.9 million in Q4 2025, $58.4 million in Q3 2025, and $36.6 million in Q2 2025.